Literature DB >> 17899326

Molecular mobility, thermodynamics and stability of griseofulvin's ultraviscous and glassy states from dynamic heat capacity.

E Tombari1, S Presto, G P Johari, Ravi M Shanker.   

Abstract

PURPOSE: To determine the calorimetric relaxation time needed for modeling griseofulvin's stability against crystallization during storage.
METHODS: Both temperature-modulated and unmodulated scanning calorimetry have been used to determine the heat capacity of griseofulvin in the glassy and melt state.
RESULTS: The calorimetric relaxation time, tau cal, of its melt varies with the temperature T according to the relation, tau cal [s] = 10(-13.3) exp [2, 292 /(T[K] - 289.5)] , and the distribution of relaxation times parameter is 0.67. The unrelaxed heat capacity of the griseofulvin melt is equal to its vibrational heat capacity.
CONCLUSIONS: Griseofulvin neither crystallizes on heating to 373 K at 1 K/h rate, nor on cooling. Molecular mobility and vibrational heat capacity measured here are more reliable for modeling a pharmaceutical's stability against crystallization than the currently used kinetics-thermodynamics relations, and molecular mobility in the (fixed structure) glassy state is much greater than the usual extrapolation from the melt state yields. Molecular relaxation time of the glassy state of griseofulvin is about 2 months at 298 K, and longer at lower temperatures. It would spontaneously increase with time. If the long-range motions alone were needed for crystallization, griseofulvin would become more stable against crystallization during storage.

Mesh:

Substances:

Year:  2007        PMID: 17899326     DOI: 10.1007/s11095-007-9444-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

Review 1.  Amorphous pharmaceutical solids: preparation, characterization and stabilization.

Authors:  L Yu
Journal:  Adv Drug Deliv Rev       Date:  2001-05-16       Impact factor: 15.470

2.  What is the true solubility advantage for amorphous pharmaceuticals?

Authors:  B C Hancock; M Parks
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

3.  Estimation of the fragility index of indomethacin by DSC using the heating and cooling rate dependency of the glass transition.

Authors:  Joaquim J Moura Ramos; Raquel Taveira-Marques; Hermínio P Diogo
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534

Review 4.  Amorphous drug delivery systems: molecular aspects, design, and performance.

Authors:  Aditya Mohan Kaushal; Piyush Gupta; Arvind Kumar Bansal
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2004       Impact factor: 4.889

5.  Classification of secondary relaxation in glass-formers based on dynamic properties.

Authors:  K L Ngai; M Paluch
Journal:  J Chem Phys       Date:  2004-01-08       Impact factor: 3.488

6.  Spontaneous liquifaction of isomerizable molecular crystals.

Authors:  E Tombari; C Ferrari; G Salvetti; G P Johari
Journal:  J Chem Phys       Date:  2007-01-14       Impact factor: 3.488

7.  Dynamic heat capacity and relaxation time of ultraviscous melt and glassy acetaminophen.

Authors:  E Tombari; S Presto; G P Johari; Ravi M Shanker
Journal:  J Pharm Sci       Date:  2006-05       Impact factor: 3.534

Review 8.  Characteristics and significance of the amorphous state in pharmaceutical systems.

Authors:  B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1997-01       Impact factor: 3.534

9.  Heat capacity of tetrahydrofuran clathrate hydrate and of its components, and the clathrate formation from supercooled melt.

Authors:  E Tombari; S Presto; G Salvetti; G P Johari
Journal:  J Chem Phys       Date:  2006-04-21       Impact factor: 3.488

10.  Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures.

Authors:  B C Hancock; S L Shamblin; G Zografi
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

View more
  2 in total

1.  Fast surface crystallization of amorphous griseofulvin below T g.

Authors:  Lei Zhu; Janan Jona; Karthik Nagapudi; Tian Wu
Journal:  Pharm Res       Date:  2010-04-23       Impact factor: 4.200

2.  Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.

Authors:  Sharad B Murdande; Michael J Pikal; Ravi M Shanker; Robin H Bogner
Journal:  Pharm Res       Date:  2010-09-22       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.